Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EMILY RISER

NPI
1124115068
CMS profile
1310558
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$33,044.63

194 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EMILY RISER

NPI 1124115068 · CMS profile ID 1310558

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124115068?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EMILY RISER, NPI 1124115068, CMS profile ID 1310558. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124115068?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). EMILY RISER, NPI 1124115068, CMS profile ID 1310558. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124115068?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
EMILY RISER, NPI 1124115068, CMS profile ID 1310558, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 194 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1124115068?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

194 matching records · $33,044.63 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 194 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 194.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $17.0606/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120249229 CMS
ABBVIE INC. $18.4006/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105951893 CMS
Celgene Corporation $16.6306/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101189659 CMS
Kedrion Biopharma, Inc. $17.0506/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125860745 CMS
Genentech, Inc. $28.0805/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133007363 CMS
TG Therapeutics, Inc. $110.8005/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887550 CMS
Novartis Pharmaceuticals Corporation $47.0305/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087157727 CMS
Alexion Pharmaceuticals, Inc. $28.7405/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110545473 CMS
Mallinckrodt Hospital Products Inc. $8.0505/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145127224 CMS
ARGENX US, INC. $24.9405/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142150840 CMS
Amgen Inc. $22.7805/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111688618 CMS
Neurocrine Biosciences, Inc. $29.1705/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150827689 CMS
TG Therapeutics, Inc. $930.0005/22/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887670 CMS
Novartis Pharmaceuticals Corporation $19.6905/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087157723 CMS
TG Therapeutics, Inc. $20.4605/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887558 CMS
Biogen, Inc. $16.2705/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104808711 CMS
Genentech USA, Inc. $18.2405/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133007347 CMS
Mallinckrodt Hospital Products Inc. $22.7005/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145127220 CMS
Eisai Inc. $19.9605/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110743909 CMS
Alexion Pharmaceuticals, Inc. $11.6905/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110532687 CMS
EMD Serono, Inc. $13.8905/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120238026 CMS
Neurocrine Biosciences, Inc. $19.7005/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150860027 CMS
PFIZER INC. $21.4705/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131321561 CMS
Celgene Corporation $25.9605/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101189655 CMS
UCB, Inc. $22.5105/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143119390 CMS
TG Therapeutics, Inc. $24.7004/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887542 CMS
Mallinckrodt Hospital Products Inc. $18.0904/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145127216 CMS
Neurocrine Biosciences, Inc. $31.6104/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150823385 CMS
Amgen Inc. $11.4504/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111688616 CMS
Biogen, Inc. $15.6004/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104808709 CMS
Novartis Pharmaceuticals Corporation $8.7404/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087157719 CMS
Novartis Pharmaceuticals Corporation $4.6804/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087157721 CMS
MITSUBISHI TANABE PHARMA AMERICA, INC. $23.0404/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144512181 CMS
PFIZER INC. $23.3604/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131335096 CMS
EMD Serono, Inc. $22.0004/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120215500 CMS
Lilly USA, LLC $18.7404/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1134971902 CMS
ANI Pharmaceuticals, Inc. $30.0404/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091172870 CMS
Celgene Corporation $3.8404/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101189653 CMS
PFIZER INC. $22.1704/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131210536 CMS
Alexion Pharmaceuticals, Inc. $25.8204/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110538503 CMS
Alexion Pharmaceuticals, Inc. $96.4404/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110547368 CMS
EMD Serono, Inc. $25.1504/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120238022 CMS
TG Therapeutics, Inc. $45.1504/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887544 CMS
Genentech USA, Inc. $23.8504/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133007343 CMS
Amgen Inc. $24.2703/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111688614 CMS
EMD Serono, Inc. $3,450.0003/27/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120279950 CMS
Neurocrine Biosciences, Inc. $18.7603/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150863075 CMS
Alexion Pharmaceuticals, Inc. $28.2803/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110546033 CMS
EMD Serono, Inc. $2,780.0003/25/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120275238 CMS
PFIZER INC. $23.5503/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131164803 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $107,223.84 224
PY2020 $36,147.40 77
PY2021 $6,132.24 88
PY2022 $11,191.45 105
PY2023 $15,500.20 174
PY2024 $33,044.63 194
PY2025 $22,116.50 193

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,175,109.62 171
PY2024 Recipient $1,080.75 1
PY2024 Principal investigator $1,237,705.26 128
PY2023 Recipient $396.11 1
PY2023 Principal investigator $1,064,370.48 127
PY2022 Principal investigator $1,161,027.81 50
PY2021 Principal investigator $760,871.64 27
PY2020 Principal investigator $398,777.26 18
PY2019 Principal investigator $68,231.37 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

171 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $2,738.00 12/19/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570642
Principal investigator 1 GENZYME CORPORATION $43,250.55 12/15/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152893
Principal investigator 1 Genentech, Inc. $8,725.00 12/15/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211570562
Principal investigator 1 TG Therapeutics, Inc. $2,853.83 12/09/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199687
Principal investigator 1 Genentech, Inc. $1,892.00 12/04/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211570565
Principal investigator 1 TG Therapeutics, Inc. $98,200.00 11/30/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199691
Principal investigator 1 Genentech, Inc. $2,442.00 11/25/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570638
Principal investigator 1 TG Therapeutics, Inc. $2,401.74 11/25/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199681
Principal investigator 1 GENZYME CORPORATION $36,919.84 11/17/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152865
Principal investigator 1 GENZYME CORPORATION $33,762.76 11/17/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152873
Principal investigator 1 GENZYME CORPORATION $12,237.81 11/17/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152879
Principal investigator 1 Genentech, Inc. $8,390.00 11/13/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211570558
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,771.00 11/01/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190313863
Principal investigator 1 TG Therapeutics, Inc. $1,497.08 11/01/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199685
Principal investigator 1 TG Therapeutics, Inc. $109,250.00 11/01/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199689
Principal investigator 1 Genentech, Inc. $2,678.00 10/28/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211570550
Principal investigator 1 Genentech, Inc. $23,109.00 10/28/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211570553
Principal investigator 1 Genentech, Inc. $3,307.00 10/16/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211570546
Principal investigator 1 Genentech, Inc. $16,883.00 10/15/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570634
Principal investigator 1 TG Therapeutics, Inc. $2,401.74 10/15/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199679
Principal investigator 1 GENZYME CORPORATION $61,769.15 10/14/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152850
Principal investigator 1 Genentech, Inc. $9,630.00 10/08/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211570522
Principal investigator 1 TG Therapeutics, Inc. $33,281.14 10/01/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199683
Principal investigator 1 TG Therapeutics, Inc. $195.04 09/30/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199665
Principal investigator 1 TG Therapeutics, Inc. $99,200.00 09/30/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199673
Principal investigator 1 Roche Products Limited $618.00 09/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570852
Principal investigator 1 Roche Products Limited $618.00 09/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570856
Principal investigator 1 Roche Products Limited $618.00 09/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570860
Principal investigator 1 Roche Products Limited $618.00 09/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570864
Principal investigator 1 Roche Products Limited $477.30 09/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570867
Principal investigator 1 Roche Products Limited $618.00 09/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570872
Principal investigator 1 Roche Products Limited $618.00 09/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570877
Principal investigator 1 Roche Products Limited $618.00 09/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570881
Principal investigator 1 GENZYME CORPORATION $32,128.69 09/22/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152816
Principal investigator 1 Genentech, Inc. $118,296.00 09/22/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211570533
Principal investigator 1 Genentech, Inc. $27,765.00 09/22/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211570542
Principal investigator 1 Genentech, Inc. $3,601.00 09/19/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211570526
Principal investigator 1 Genentech, Inc. $1,725.00 09/18/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211570537
Principal investigator 1 GENZYME CORPORATION $3,000.00 09/15/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152796
Principal investigator 1 GENZYME CORPORATION $500.00 09/03/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152746
Principal investigator 1 GENZYME CORPORATION $4,400.00 09/03/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152749
Principal investigator 1 GENZYME CORPORATION $125.00 09/03/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152756
Principal investigator 1 GENZYME CORPORATION $4,850.00 09/03/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152762
Principal investigator 1 GENZYME CORPORATION $1,175.00 09/03/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152771
Principal investigator 1 GENZYME CORPORATION $37,380.79 09/03/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152789
Principal investigator 1 GENZYME CORPORATION $125.00 09/03/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152801
Principal investigator 1 GENZYME CORPORATION $125.00 09/03/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152806
Principal investigator 1 TG Therapeutics, Inc. $74,147.78 08/31/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199663
Principal investigator 1 TG Therapeutics, Inc. $76,800.00 08/31/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199671
Principal investigator 1 Genentech, Inc. $13,638.00 08/26/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211570518
Principal investigator 1 Genentech, Inc. $1,681.00 08/26/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570604
Principal investigator 1 Genentech, Inc. $1,550.00 08/26/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570614
Principal investigator 1 Genentech, Inc. $5,838.00 08/22/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211570510
Principal investigator 1 Genentech, Inc. $3,096.00 08/22/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570609
Principal investigator 1 Genentech, Inc. $17,507.00 08/21/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570625
Principal investigator 1 Genentech, Inc. $2,088.00 08/20/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211570514
Principal investigator 1 Genentech, Inc. $9,261.00 08/20/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570621
Principal investigator 1 Genentech, Inc. $9,261.00 08/19/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570600
Principal investigator 1 Genentech, Inc. $2,884.00 08/19/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570618
Principal investigator 1 GENZYME CORPORATION $12,012.81 08/18/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152741
Principal investigator 1 TG Therapeutics, Inc. $1,334.30 08/18/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199677
Principal investigator 1 Genentech, Inc. $1,892.00 08/15/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211570529
Principal investigator 1 GENZYME CORPORATION $19,091.10 08/11/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152731
Principal investigator 1 GENZYME CORPORATION $24,281.25 08/11/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152737
Principal investigator 1 Genentech, Inc. $3,500.00 08/11/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570630
Principal investigator 1 TG Therapeutics, Inc. $82,000.00 07/31/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199669
Principal investigator 1 TG Therapeutics, Inc. $4,500.00 07/22/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199667
Principal investigator 1 GENZYME CORPORATION $38,293.50 07/21/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152712
Principal investigator 1 Genentech, Inc. $8,034.00 07/21/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211570506
Principal investigator 1 Genentech, Inc. $16,551.00 07/21/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570595
Principal investigator 1 TG Therapeutics, Inc. $7,472.08 07/21/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199675
Principal investigator 1 GENZYME CORPORATION $31,422.30 07/02/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152700
Principal investigator 1 GENZYME CORPORATION $26,085.68 07/02/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152705
Principal investigator 1 Genentech, Inc. $1,216.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211570482
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570743
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570747
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570750
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570755
Principal investigator 1 Roche Products Limited $263.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570759
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570763
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570767
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570771
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570774
Principal investigator 1 Roche Products Limited $263.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570779
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570784
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570789
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570792
Principal investigator 1 Roche Products Limited $263.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570797
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570801
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570805
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570810
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570814
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570819
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570825
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570828
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570833
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570837
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570841
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570845
Principal investigator 1 Roche Products Limited $618.00 06/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570848
Principal investigator 1 GENZYME CORPORATION $14,502.60 06/23/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152696
Principal investigator 1 Genentech, Inc. $4,718.00 06/17/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570569
Principal investigator 1 Genentech, Inc. $13,469.00 06/03/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211570477
Principal investigator 1 TG Therapeutics, Inc. $13,200.00 06/01/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199607
Principal investigator 1 TG Therapeutics, Inc. $26,750.00 06/01/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199631
Principal investigator 1 GENZYME CORPORATION $16,000.00 05/27/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152616
Principal investigator 1 GENZYME CORPORATION $12,012.81 05/27/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152622
Principal investigator 1 Genentech, Inc. $7,464.00 05/21/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570574
Principal investigator 1 GENZYME CORPORATION $4,000.00 05/12/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152604
Principal investigator 1 GENZYME CORPORATION $59,791.99 05/12/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152611
Principal investigator 1 Genentech, Inc. $41,631.00 05/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211570498
Principal investigator 1 Genentech, Inc. $9,643.00 05/08/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211570494
Principal investigator 1 TG Therapeutics, Inc. $4,500.00 05/06/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199605
Principal investigator 1 GENZYME CORPORATION $14,300.22 05/05/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152550
Principal investigator 1 Genentech, Inc. $2,442.00 04/25/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570590
Principal investigator 1 TG Therapeutics, Inc. $4,500.00 04/23/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199603
Principal investigator 1 TG Therapeutics, Inc. $4,500.00 04/23/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199657
Principal investigator 1 TG Therapeutics, Inc. $4,500.00 04/23/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199659
Principal investigator 1 Genentech, Inc. $1,725.00 04/15/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211570502
Principal investigator 1 GENZYME CORPORATION $14,491.05 04/14/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152535
Principal investigator 1 GENZYME CORPORATION $10,576.40 04/14/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152579
Principal investigator 1 TG Therapeutics, Inc. $3,202.32 04/14/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199651
Principal investigator 1 GENZYME CORPORATION $11,595.15 04/02/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152466
Principal investigator 1 GENZYME CORPORATION $49,151.03 04/02/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152471
Principal investigator 1 Genentech, Inc. $14,510.00 04/02/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570586
Principal investigator 1 Novartis Pharmaceuticals Corporation $87,370.67 03/31/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES PC
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190313007
Principal investigator 1 TG Therapeutics, Inc. $2,600.00 03/31/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199597
Principal investigator 1 TG Therapeutics, Inc. $17,600.00 03/31/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199629
Principal investigator 1 Roche Products Limited $618.00 03/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570658
Principal investigator 1 Roche Products Limited $618.00 03/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570668
Principal investigator 1 Roche Products Limited $618.00 03/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570672
Principal investigator 1 Roche Products Limited $618.00 03/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570675
Principal investigator 1 Roche Products Limited $618.00 03/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570684
Principal investigator 1 Roche Products Limited $618.00 03/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570692
Principal investigator 1 Roche Products Limited $618.00 03/24/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570700
Principal investigator 1 GENZYME CORPORATION $52,171.88 03/10/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152390
Principal investigator 1 Novartis Pharmaceuticals Corporation $82,791.84 02/28/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES PC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190313009
Principal investigator 1 TG Therapeutics, Inc. $7,500.00 02/28/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199595
Principal investigator 1 TG Therapeutics, Inc. $33,000.00 02/28/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199627
Principal investigator 1 Genentech, Inc. $11,571.00 02/20/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211570490
Principal investigator 1 Genentech, Inc. $2,678.00 02/14/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211570487
Principal investigator 1 Genentech, Inc. $2,738.00 02/14/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570582
Principal investigator 1 TG Therapeutics, Inc. $4,500.00 02/11/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199601
Principal investigator 1 TG Therapeutics, Inc. $4,500.00 02/11/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199653
Principal investigator 1 TG Therapeutics, Inc. $4,500.00 02/11/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199655
Principal investigator 1 TG Therapeutics, Inc. $4,500.00 02/11/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199661
Principal investigator 1 GENZYME CORPORATION $14,735.70 02/10/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152425
Principal investigator 1 TG Therapeutics, Inc. $4,500.00 02/07/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199599
Principal investigator 1 TG Therapeutics, Inc. $600.00 02/01/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199625
Principal investigator 1 TG Therapeutics, Inc. $7,600.00 01/31/2025 Non-covered Recipient Entity
Alabama Neurology Associates
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199593
Principal investigator 1 GENZYME CORPORATION $21,864.15 01/27/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226152419
Principal investigator 1 Alexion Pharmaceuticals, Inc. $9,224.00 01/22/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) No dispute reported 06/30/2026 1185551451
Principal investigator 1 Genentech, Inc. $9,270.00 01/22/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOC PC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211570577
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570646
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570650
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570654
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570661
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570664
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570680
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570688
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570696
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570705
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570709
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570712
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570717
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570721
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570726
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570730
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570735
Principal investigator 1 Roche Products Limited $618.00 01/09/2025 Non-covered Recipient Entity
ALABAMA NEUROLOGY ASSOCIATES
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211570739
Principal investigator 1 GENZYME CORPORATION $37,060.55 01/06/2025 Non-covered Recipient Entity
Alabama Neurology Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226152531